Using bacteriophages to predict treatment outcomes in chronic lung infections
Official title: Bacteriophage as a predictive biomarker in chronic Pseudomonas airway disease
Funded at Children's Hospital of Los Angeles · NIH-10912032 · Data updated 2026-11-12
This study is looking at how a specific virus that targets bacteria might help us understand and improve treatments for lung infections in people with cystic fibrosis, and we’d love for patients to share their samples and experiences to help us find better ways to fight these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hospital of Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 22, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $199,044 |
| NIH project number | 5K23HL169902-02 |
| Project ID | NIH-10912032 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 21 and older with cystic fibrosis who experience chronic lung infections.
✕Less likely to help
Patients without cystic fibrosis or those who do not have chronic lung infections caused by Pseudomonas aeruginosa may not benefit from this research.
What this research studies
This research investigates the role of bacteriophages, specifically the Pf bacteriophage, in chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis. The study aims to understand how these bacteriophages contribute to antibiotic tolerance and whether they can serve as predictive biomarkers for selecting effective inhalational therapies. By analyzing respiratory samples from patients, the research seeks to uncover mechanisms that could improve treatment strategies and patient outcomes. Patients may be involved in providing samples and data to help advance this important work.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for chronic lung infections in cystic fibrosis patients, potentially improving their lung function and quality of life.
How similar studies have gone: Previous research has shown promising results regarding the role of bacteriophages in lung disease, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Children's Hospital of Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Burgener, Elizabeth Bendig — Children's Hospital of Los Angeles
- Study coordinator: Burgener, Elizabeth Bendig
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.